Darren Jun Hao Tan
Overview
Explore the profile of Darren Jun Hao Tan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
92
Citations
1415
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Danpanichkul P, Suparan K, Auttapracha T, Tothanarungroj P, Kongarin S, Rakwong K, et al.
Mayo Clin Proc
. 2025 Feb;
PMID: 39945699
Objective: To explore the increasing incidence of gastrointestinal (GI) cancers and related risk factors in younger patients. Patient And Methods: We used data from the Global Burden of Disease Study...
2.
Koh B, Danpanichkul P, Wang M, Tan D, Ng C
eGastroenterology
. 2025 Feb;
1(2):e100002.
PMID: 39944000
Hepatocellular carcinoma (HCC) is a major cause of cancer-related deaths worldwide. This review explores the recent progress in the application of artificial intelligence (AI) in radiological diagnosis of HCC. The...
3.
Tham E, Tan D, Danpanichkul P, Ng C, Syn N, Koh B, et al.
Liver Int
. 2025 Feb;
45(3):e70001.
PMID: 39927433
Background And Aim: The burden of cirrhosis and other chronic liver diseases has changed in recent years due to shifts in the contributing aetiologies. We estimated the burden of cirrhosis...
4.
Cho E, Law M, Yu Z, Yong J, Tan C, Tan E, et al.
Dig Dis Sci
. 2024 Dec;
70(2):533-542.
PMID: 39708260
Background: Major society guidelines recommend transarterial chemoembolization (TACE) as the standard of care for intermediate-stage hepatocellular carcinoma (HCC) patients. However, predicting treatment response remains challenging. Aims: As artificial intelligence (AI)...
5.
Tan E, Danpanichkul P, Yong J, Yu Z, Tan D, Lim W, et al.
J Hepatol
. 2024 Oct;
PMID: 39481652
Background & Aims: The epidemiology of adult primary liver cancer continues to evolve, owing to the increasing prevalence of metabolic disease, rising alcohol consumption, advances in vaccination for HBV, and...
6.
Tan D, Tamaki N, Kim B, Wijarnpreecha K, Aboona M, Faulkner C, et al.
Aliment Pharmacol Ther
. 2024 Oct;
61(2):278-285.
PMID: 39462858
Background: Major society guidelines recommend the fibrosis-4 index (FIB-4) as the initial step to risk stratifying people with metabolic dysfunction-associated steatotic liver disease (MASLD). We aimed to evaluate the proportion...
7.
Tham E, Lim R, Koh B, Tan D, Ng C, Law M, et al.
Clin Gastroenterol Hepatol
. 2024 Oct;
PMID: 39461458
Background And Aims: Chronic liver disease is a known risk factor for cholangiocarcinoma (CCA), but the proportion of people with CCA who have concurrent chronic liver disease is unclear. We...
8.
Lim W, Poh C, Tan B, Ng C, Tan D, Lim X, et al.
Gastro Hep Adv
. 2024 Aug;
1(2):150-159.
PMID: 39131130
Background And Aims: With existing literature focusing on general quality of life, the magnitude and impact of depression among recipients after liver transplantation (LT) is unclear. Hence, we aim to...
9.
Zeng R, Ong C, Ong E, Chung C, Lim W, Xiao J, et al.
Clin Gastroenterol Hepatol
. 2024 Jul;
22(12):2394-2402.e15.
PMID: 38987014
Background: Although the burden of alcohol-associated hepatocellular carcinoma (HCC) is increasing with rising alcohol consumption, clinical presentation and outcomes of alcohol-associated HCC have not been systematically assessed. We aimed to...
10.
Fu C, Teng M, Tung D, Ramadoss V, Ong C, Koh B, et al.
Dig Dis Sci
. 2024 Jun;
69(9):3195-3205.
PMID: 38940975
Background: To overcome the limitations of the term "non-alcoholic fatty liver disease" (NAFLD), the term metabolic-associated steatotic liver disease (MASLD) was introduced. While epidemiologic studies have been conducted on MASLD,...